GlassScriptPhysician profile
Hossein Haghbin
NPI 1710472667
$3,427.25
in general payments reported to CMS, 2019-2025
15 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,011 · 2023: $1,691 · 2024: $601 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.57 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.82 | 2022-2024 | |
| Janssen Biotech, INC. | $676.54 | 2022-2024 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $252.15 | 2024-2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $242.02 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $227.56 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $201.60 | 2022-2024 | Epclusa |
| Cook Medical LLC | $145.83 | 2023 | Fusion |
| Janssen Scientific Affairs, LLC | $145.40 | 2022-2024 | Stelara |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.33 | 2022 | |
| Intercept Pharmaceuticals, INC. | $116.19 | 2022 | |
| Capsovision, INC. | $111.64 | 2023 | Capsocam Plus |
| Qol Medical, LLC | $107.10 | 2023 | Sucraid |
| Boston Scientific Corporation | $63.23 | 2023 | Exalt Model D |
| Merck Sharp & Dohme LLC | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hossein Haghbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.